从小岛移植到β细胞再生:关于1型糖尿病的β细胞治疗方法的最新情况
Asef Azad1, Hasan Ali Altunbas2, Ayse Esra Manguoglu1
1Department of Medical Biology, Faculty of Medicine, Akdeniz University, Antalya, Turkey.
Expert review of endocrinology & metabolism
|May 2, 2024
概括
1型糖尿病 (T1D) 治疗可以通过使用干细胞再生胰岛素产生β细胞,并通过工程T细胞保护它们免受免疫攻击来推进. 这种双重方法为T1D的潜在治疗提供了有希望的途径.
科学领域:
- 免疫学 免疫学 免疫学
- 内分泌学 在内分泌学.
- 再生医学是一种再生医学.
背景情况:
- 1型糖尿病 (T1D) 涉及免疫媒介破坏胰岛素分泌β细胞,导致视网膜病变和病变等并发症.
- 目前的T1D管理策略旨在治疗正常血糖症,但治疗方法需要β细胞的再生和保护.
研究的目的:
- 探索1型糖尿病治疗的先进策略,重点关注β细胞再生和免疫保护.
- 为了研究多能干细胞和工程T细胞的潜力,用于治疗T1D协议.
主要方法:
- 利用多能干细胞分化产生无限量的β细胞来源.
- 采用化学抗原受体 (CAR) 技术来设计胰腺特异性调节T细胞以诱导免疫耐受性.
主要成果:
- 多能干细胞分化为β细胞再生提供了一个可持续的来源.
- 工程T细胞显示诱导免疫耐受性的潜力,保护β细胞免受自身免疫攻击.
结论:
- 通过干细胞的β细胞再生与通过工程T细胞的免疫保护相结合,为1型糖尿病提供了一种新的治疗策略.
- 这种综合方法有望为开发T1D治疗方案提供希望.
相关概念视频
Tissue Renewal without Stem Cells
1.7K
After cellular or tissue damage, the resident stem cells present in the human body can locally repair and regenerate the damaged tissue or organ. However, even though some tissues do not have stem cells, they can repair and regenerate with the help of pre-existing cells. For example, beta cells of the pancreas and hepatocytes of the liver can divide to renew and regenerate the tissue. Here, both cell division and cell death are well regulated by homeostasis.
However, failure of such a system...
However, failure of such a system...
1.7K
Insulin: Biosynthesis, Chemistry, and Preparation
374
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
374
Diabetes Mellitus: Overview and Type I Subtype
2.6K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.6K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.2K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.2K
iPS Cell Differentiation
2.7K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.7K
Glucagon-like Receptor Agonists
319
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
319


